The time is now for a more predictive approach to preclinical neurotherapeutic drug development

BRAIN DISORDERS: A WORLDWIDE CRISIS & CHALLENGE FOR PHARMA DRUG DEVELOPMENT

Brain Disorders A Challenge For Pharma Drug Development

Our Solution

The power of our neural circuit platform enables our clients to expedite and de-risk preclinical neurotherapeutic drug development with an objective, quantitative, data-driven approach that informs better decisions predictive of clinical success.

Power of Inscopix Neural Circuits Platform
Key Benefits of the Inscopix Platform

Key Benefits of the Inscopix Platform

  • DATA-DRIVEN: Provides a direct readout from therapeutically targeted circuits, cell types, and brain regions with a direct link to behavior in real time
  • MECHANISM OF ACTION: Establishes a clear link between circuit pathophysiology, target engagement, and behavioral efficacy endpoints
  • LONGITUDINAL STUDIES: Facilitates in-life measures enabling multi-drug, multi-dose, intra-subject experimental designs for acute and chronic drug testing

Preclinical Applications of Inscopix Platforms

By targeting neural circuits, the Inscopix platform provides direct in vivo readouts of disease progression and therapeutic intervention empowering researchers to make critical go, no-go decisions and effective translation of preclinical data.

Pipeline for Preclinical Drug Development

Disease Mechanism and Novel Target Discovery

The Inscopix platform provides unprecedented insight into the mechanisms of disease that drive symptoms, the early signatures and progression of disease critical for early intervention, and the cell types and pathways in the brain that serve as the most promising targets for next-generation precision therapeutics.

For an example study on Chronic Pain, read Corder et al., 2019

Improved Pharmacodynamic Readouts

The platform directly facilitates efforts to profile and prioritize compounds in development.

Pharmacokinetics/Pharmacodynamics (PK/PD)

  • Target engagement
  • Dose optimization
  • Compound comparisons

For an example study on Zolpidem, read Berdyevva et al., 2019

Predictive Efficacy Assays

Over 50% of therapeutic candidates for brain disorders fail due to a lack of clinical efficacy that was not predicted during preclinical testing. The Inscopix platform enables measurement of disease-related circuit pathophysiology and the degree to which candidate therapies can correct aberrant and dysregulated circuits - a more sensitive and predictive assay of clinical efficacy than animal behavior alone or other standard measures.

For an example study on Parkinson's Disease, read Parker et al., 2018

We partner with the best

Johnson
Lundbeck
Novartis
Lilly
Astellas

Working with Inscopix and their support team was crucial to our ability to collect 12 TB of high-quality imaging data in three months – effectively boosting our understanding of in vivo circuit pharmacology!

Paolo Botta, PhD - Senior Research Scientist | Lundbeck

You can partner with us in two ways

Inscopix blends the best of cutting-edge neurotechnology, a fast-paced startup environment, and a world-class team of neuroscientists, data scientists, and engineers.

Establish the Inscopix platform in-house

Collaborate with us for customized solutions

Contact Us

Image CAPTCHA
I'm inquiring for: